Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Investigational Vaccine in Reducing the Incidence of Anogenital Warts in Young Men.

Trial Profile

An Investigational Vaccine in Reducing the Incidence of Anogenital Warts in Young Men.

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Aug 2018

At a glance

  • Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
  • Indications Anal cancer; Anal intraepithelial neoplasia; Genital warts; Human papillomavirus infections; Penile cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 05 Jun 2018 Results reporting the end-of-study analysis of a long-term follow up (LTFU) extension study that assessed the effectiveness and immunogenicity of the qHPV vaccine through 10 years after the first dose presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 11 Apr 2017 Status changed from active, no longer recruiting to completed.
    • 26 Mar 2017 This trial has been completed in Spain.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top